Day 1 – 21 September 2021
|Interactive Poster session 1|
|10:30–11:30||Industry Symposium 2|
|11:35–12:20||Plenary Session 1
Genetic and epigenetic insights in IgAN
Krzysztof Kiryluk: Where are we going next with genetic studies in IgAN?
Jonathan Barratt: RNA interference in IgAN
Alexandra Cambier: Is there a link between collagen IV mutations and IgAN?
|12:50–13:50||Free Communications 1|
|13:55–14:55||Panel Discussion 1
Patient panel: The challenges of living with IgA nephropathy
|15:00–15:30||Industry Symposium 6a|
|15:35–16:20||Plenary Session 2
What role does complement activation play in IgAN?
Richard Lafayette: Complement in IgAN what we know and what we don't
Hong Zhang: A role for the lectin pathway?
Nick Medjeral-Thomas: A role for the alternative pathway?
|16:35–17:20||Plenary Session 3
Where do we go next with the kidney biopsy in IgAN?
Ian Roberts: What next for the Oxford Classification?
Peter Boor: The use of Artificial Intelligence in kidney biopsy evaluation
Rafael Kramann: Taking the Omics Revolution into the kidney biopsy
|17:25–18:10||Plenary Session 4
B cells & IgA
Jennifer Gommerman: Mucosal immune cells: Saints or Sinners?
Jan Novak: 25 years since IgA1 glycosylation changes were first described-what will the next 25 years bring?
Loreto Gesualdo: Is IgAN a disease of mistrafficking B cells?
|18:15–19:15||Industry Symposium 2|
|19:20–20:20||Industry Symposium 1|
|20:25–21:10||Interactive Poster session 2|
All times in the symposium programme are in Central European Summer Time – CEST (UTC + 2).